Evidence map›Paper›PMID 41047355›Full record

ArticleMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2026

Comparison of MR Imaging of High-grade Serous Carcinomas with and without Homologous Recombination-deficiency.

Tsukasa Saida, Ayumi Shikama, Miki Yoshida, Taishi Amano, Toshitaka Ishiguro, Masafumi Sakai, Sodai Hoshiai, Toyomi Satoh, Takahito Nakajima

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tsukasa SaidaDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0003-4530-7375
Ayumi ShikamaDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-5633-1816
Miki YoshidaDepartment of Diagnostic and Interventional Radiology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0001-9532-5411
Taishi AmanoDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-7321-980X
Toshitaka IshiguroDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0001-5018-4248
Masafumi SakaiDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-5048-992X
Sodai HoshiaiDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-3558-0258
Toyomi SatohDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-6929-5463
Takahito NakajimaDepartment of Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0001-6704-2297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMRI findings of high-grade serous carcinoma (HGSC) with and without homologous recombination deficiency (HRD) were compared to explore the feasibility of using MRI as a genetic predictor.

methodsWe retrospectively reviewed MRI data from HRD-positive and HRD-negative HGSC and evaluated tumor size, appearance, apparent diffusion coefficient (ADC), time-intensity curve, and several dynamic contrast-enhanced curve descriptors. Age, primary site, tumor stage, bilaterality, presence of lymph node metastasis, presence of peritoneal metastasis, and tumor marker levels were also compared.

resultsForty-eight patients with HRD-positive HGSC (17 patients with BRCA1 variant, 9 patients with BRCA2 variant, and 22 without BRCA variants) and 18 patients with HRD-negative HGSC were included. The HRD-negative patients' mean age was 67 years, which was significantly higher than that of the HRDpositive patients (60 years, P = 0.011). High-risk time-intensity curve (TIC) patterns were more common in HRD-negative tumors (94%) than in HRD-positive tumors (63%; P = 0.047). Tumors without HRD exhibited significantly higher wash-in rates (P = 0.023). Additionally, unresectable lymph node metastases were significantly more frequent in HRD-negative patients (P = 0.013). No significant differences were observed in the other evaluated factors.

conclusionThe comparison between HGSC with and without HRD revealed that HGSC without HRD was significantly associated with older age, a higher likelihood of exhibiting a high-risk TIC pattern, a higher wash-in rate, and a higher frequency of unresectable lymph node metastasis.

Indexed as

Cystadenocarcinoma, SerousHomologous RecombinationMagnetic Resonance ImagingOvarian NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingRetrospective Studiescancerhigh-grade serous carcinomahomologous recombination deficientmagnetic resonance imagingovary

Identifiers

PMID41047355
PMCPMC13041242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.